Original Article

A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.

Bin Xiong, Chun-Shan Gui, Xiao-Ying Xu, Cheng Luo, Jing Chen, Hai-Bin Luo, Li-Li Chen, Guo-Wei Li, Tao Sun, Chang-Ying Yu, Li-Duo Yue, Wen-Hu Duan, Jin-Kang Shen, Lei Qin, Tei-Liu Shi, Yi-Xue Li, Kai-Xian Chen, Xiao-Min Luo, Xu Shen, Jian-Hua Shen, Hua-Liang Jiang

Abstract

AIM: To constructed a three-dimensional (3D) model for the 3C like (3CL) proteinase of SARS coronavirus (SARS-CoV), and to design inhibitors of the 3CL proteinase based on the 3D model. METHODS: Bioinformatics analyses were performed to search the homologous proteins of the SARS-CoV 3CL proteinase from the GenBank and PDB database. A 3D model of the proteinase was constructed by using homology modeling technique. Targeting to the 3D model and its X-ray crystal structure of the main proteinase (Mpro) of transmissible gastroenteritis virus (TGEV), virtual screening was performed employing molecular docking method to identify possible 3CL proteinase inhibitors from small molecular databases. RESULTS: Sequence alignment indicated that the SARS-CoV 3CL proteinase was extremely homologous to TGEV Mpro, especially the substrate-binding pocket (active site). Accordingly, a 3D model for the SARS-CoV 3CL proteinase was constructed based on the crystal structure of TGEV Mpro. The 3D model adopts a similar fold of the TGEV Mpro, its structure and binding pocket feature are almost as same as that of TGEV Mpro. The tested virtual screening indicated that 73 available proteinase inhibitors in the MDDR database might dock into both the binding pockets of the TGEV Mpro and the SARS-CoV 3CL proteinase. CONCLUSIONS: Either the 3D model of the SARS-CoV 3CL proteinase or the X-ray crystal structure of the TGEV Mpro may be used as a starting point for design anti-SARS drugs. Screening the known proteinase inhibitors may be an appreciated shortcut to discover anti-SARS drugs.
Keywords:

Article Options

Download Citation

Cited times in Scopus